Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer

Clinical Cancer Research

Volumn 19, Issue 22, 2013, Pages 6163-6172

  Skor, Maxwell N ^a   Wonder, Erin L ^a   Kocherginsky, Masha ^a   Goyal, Anju ^a   Hall, Ben A ^a   Cai, Yi ^a   Conzen, Suzanne D ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR ANTAGONIST; MIFEPRISTONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORTICOSTEROID BLOOD LEVEL; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DUSP1 GENE; ENZYME ANALYSIS; FEMALE; GENE EXPRESSION; GENE INDUCTION; IN VIVO STUDY; INTRACELLULAR SIGNALING; MKP1 GENE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; REGULATORY MECHANISM; SGK1 GENE; TREATMENT DURATION; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; DUAL SPECIFICITY PHOSPHATASE 1; FEMALE; GENE EXPRESSION; HORMONE ANTAGONISTS; HUMANS; IMMEDIATE-EARLY PROTEINS; MICE; MICE, SCID; MIFEPRISTONE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; PACLITAXEL; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, ESTROGEN; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84888116498     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3826     Document Type: Article

References (32)

1. Bamberger CM, Schulte HM, Chrousos GP. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr Rev 1996;17:245-61. (Pubitemid 26001083)
2. Pan D, Kocherginsky M, Conzen SD. Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptornegative breast cancer. Cancer Res 2011;71:6360-70.
3. Armaiz-Pena GN, Lutgendorf SK, Cole SW, Sood AK. Neuroendocrine modulation of cancer progression. Brain Behav Immun 2009;23:10-5.
4. McKenna NJ, O'Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 2002;108:465-74. (Pubitemid 34260872)
5. Lewis-Tuffin LJ, Cidlowski JA. The physiology of human glucocorticoid receptor beta (hGRbeta) and glucocorticoid resistance. Ann N Y Acad Sci 2006;1069:1-9. (Pubitemid 43989846)
6. Gibson S, Tu S, Oyer R, Anderson SM, Johnson GL. Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J Biol Chem 1999;274:17612-8.
7. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980;284:555-6. (Pubitemid 10070336)
8. Moran TJ, Gray S, Mikosz CA, Cozen SD. The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res 2000;60:867-72. (Pubitemid 30129517)
9. Pang D, Kocherginsky M, Krausz T, Kim SY, Conzen SD. Dexamethasone decreases xenograft response to Paclitaxel through inhibition of tumor cell apoptosis. Cancer Biol Ther 2006;5:933-40.
10. Brickley DR, Mikosz CA, Hagan CR, Conzen SD. Ubiquitinmodification of serum and glucocorticoid-induced protein kinase-1 (SGK-1). J Biol Chem 2002;277:43064-70. (Pubitemid 35285688)
11. Huang Y, Johnson KR, Norris JS, Fan W. Nuclear factor-kappaB/IkappaB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res 2000;60:4426-32. (Pubitemid 32103621)
12. Zhang C, Wenger T, Mattern J, Ilea S, Frey C, Gutwein P, et al. Clinical and mechanistic aspects of glucocorticoid-induced chemotherapy resistance in the majority of solid tumors. Cancer Biol Ther 2007;6:278-87. (Pubitemid 46641636)
13. Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD. Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res 2004;64:1757-64. (Pubitemid 38428699)
14. Mikosz CA, Brickley DR, Sharkey MS, Moran TW, Conzen SD. Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem 2001;276:16649-54.
15. Melhem A, Yamada SD, Fleming GF, Delgado B, Brickley DR, Wu W, et al. Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues. Clin Cancer Res 2009;15:3196-204.
16. Thon JN, Devine MT, Begonja AJ, Tibbitts J, Italiano JE Jr. Highcontent live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)-mediated inhibition of platelet production. Blood 2012;120:1975-84.
17. Masson MJ, Collins LA, Carpenter LD, Graf ML, Ryan PM, Bourdi M, et al. Pathologic role of stressed-induced glucocorticoids in druginduced liver injury in mice. Biochem Biophys Res Commun 2010;397:453-8.
18. Wang JD, Shi WL, Zhang GQ, Bai XM. Tissue and serum levels of steroid-hormones and RU-486 after administration of mifepristone. Contraception 1994;49:245-53.
19. Abraham VC, Towne DL, Waring JE, Warrior U, Burns DJ. Application of a high-content multiparameter cytotoxicity assay to prioritize compounds based on toxicity potential in humans. J Biomol Screening 2008;13:527-37. (Pubitemid 351905075)
20. Lu NZ, Cidlowski JA. Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes. Mol Cell 2005;18:331-42. (Pubitemid 41350538)
21. Gross KL, Oakley RH, Scoltock AB, Jewell CM, Cidlowski JA. Glucocorticoid receptor alpha isoform-selective regulation of antiapoptotic genes in osteosarcoma cells: a new mechanism for glucocorticoid resistance. Mol Endocrinol 2011;25:1087-99.
22. O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011;364:205-14.
23. Arnedos M, Bihan C, Delaloge S, Andre F. Triple-negative breast cancer: are we makingheadwayatleast? Ther Adv Med Oncol 2012;4:195-210.
24. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012;486:395-9.
25. Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, et al. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
26. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig 2011;121:2750-67.
27. He K, Woolf TF, Hollenberg PF. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486). J Pharmacol Exp Ther 1999;288:791-7. (Pubitemid 29119696)
28. Giannopoulos G, Keichline D. Species-related differences in steroidbinding specificity of glucocorticoid receptors in lung. Endocrinology 1981;108:1414-9. (Pubitemid 11079166)
29. Weitzman ED, Fukushim D, Nogeire C, Roffwarg H, Gallaghe Tf, Hellman L. 24 hour pattern of episodic secretion of cortisol in normal subjects. J Clin Endocrinol Metab 1971;40:850-5.
30. Spitz IM, Bardin CW. Drug-therapy - Mifepristone (RU-486) - a modulator of progestin and glucocorticoid action. N Engl J Med 1993;329:404-12. (Pubitemid 23219347)
31. Perrault D, Eisenhauer EA, Pritchard KI, Panasci L, Norris B, Vandenberg T, et al. Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1996;14:2709-12. (Pubitemid 26329656)
32. Heikinheimo O, Kekkonen R, Lahteenmaki P. The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action. Contraception 2003;68:421-6. (Pubitemid 38112740)